Skip to main content

Equitas Small Finance Bank may launch IPO on October 20, to raise Rs 532 crore

At the time of filing DRHP in December 2019, promoter Equitas Holdings held 95.49 percent stake in Equitas Small Finance Bank.

Equitas Small Finance Bank, the subsidiary of Equitas Holdings, may be launching its public issue on October 20, people familiar with IPO development told Moneycontrol. If it happens, it would be 12th IPO this year.

The company in consultation with merchant bankers might have fixed a price band at Rs 34-35 per share and the closing date for issue could be October 22, sources told Moneycontrol.

As per the additional information to its DRHP filed with Sebi last month, the public issue consists of a fresh issue of 8 crore equity shares and an offer for sale of 7.2 crore equity shares.



Considering the upper price band, the total issue size could be Rs 532 crore (fresh issue of Rs 280 crore and offer for sale of Rs 252 crore).

The offer includes a reservation of up to Rs 1 crore worth of shares for eligible employees of Equitas Small Finance Bank and Rs 51 crore of shares for Equitas Holdings' shareholders.

The proposed issue size, as per DRHP, included a fresh issue of Rs 550 crore and an offer for sale of 8 crore equity shares by Equitas Holdings, but later in view of the relaxation permitted by the Securities and Exchange Board of India, the issue size reduced to Rs 280 crore (fresh issue) and 7.2 crore shares (offer for sale by promoter).

Accordingly, the reservation portion of Equitas Holdings shareholders has also been revised from up to Rs 100 crore to up to Rs 51 crore and the employee reservation portion of Equitas Small Finance Bank has been revised from up to Rs 5 crore to up to Rs 1 crore.

Equitas Small Finance Bank (SFB) was the largest SFB in India in terms of number of banking outlets, and the second largest SFB in India in terms of assets under management and total deposits in Fiscal 2019, the CRISIL report said.

SFB offers a range of banking products and services to customers with a focus on serving the financially unserved and underserved customer segments in India.

At the time of filing DRHP in December 2019, promoter Equitas Holdings held 95.49 percent stake in Equitas Small Finance Bank.

JM Financial, Edelweiss Financial Services and IIFL Securities are appointed as book running lead managers to the issue.

Labels:

Comments

Post a Comment

Popular posts from this blog

Panacea Biotech shares hit 5% upper circuit after dengue vaccine completes phase I & II study

DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes, the company has said in an exchange filing. Panacea Biotech share price hit 5 percent upper circuit on the BSE on September 24 after the company completed phases I and II study of its dengue vaccine candidate DengiAIl. "Panacea Biotec Ltd. is delighted to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose liveattenuated tetravalent vaccine," the company said in an exchange filing. Live-attenuated vaccines contain weakened bacteria or viruses that trigger an immune response but do not cause disease. The company said DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes. DengiAIl has been found to be safe and well-tolerated with no serious adverse effects, the company said. After a single-dose, more than 80 percent of the participants ...
Post a Comment
Read more

Brokerages place bets on Titan, see double-digit upside in the stock

Titan can get benefits from the strong market share in the jewellery and wrist watches segment, mainly driven by a wide range of product portfolio catering mainly to the premium and value-added designer jewellery segment. After three consecutive sessions of losses, shares of Titan Company rose over a percent in morning trade on BSE on September 23. The company was dealt a severe blow by COVID-19 as the pandemic triggered strict lockdowns completely battered the retail sector. In the calendar year so far, shares of this one of the largest, most efficient and profitable specialty retailer in India are 7 percent down. The company reported a net standalone loss of Rs 270 crore for the quarter ended June 2020 as the COVID-19 pandemic hit business. The loss was higher than a CNBC-TV18 poll estimate of Rs 175 crore. Standalone revenue during the quarter declined 62.3 percent year-on-year to Rs 1,862 crore compared to the corresponding period last fiscal. Light at the end ...
Post a Comment
Read more

Check Chemcon Speciality Chemicals IPO allotment status in four simple steps

Equity shares will get credited into the accounts of eligible investors by September 30 and the listing of equity shares will be on October 1, 2020. Chemcon Speciality Chemicals, the manufacturer for pharmaceutical and oilfields industries, is expected to announce the basis of allotment early next week. As per the schedule provided by the company, the finalisation of the basis of the allotment will be done by September 28 and the initiation of refunds or unblocking of funds from ASBA account will take place on September 29. Equity shares will get credited to the accounts of eligible investors by September 30 and the listing will be on October The IPO comprised a fresh issue of Rs 165 crore and an offer for sale of Rs 153 crore by promoters. The company will utilise fresh issue proceeds for expansion of manufacturing facility, working capital requirements, and general corporate purposes. Chemcon manufactures specialised chemicals, such as Hexamethyldisilazane (HMDS) and Chloromethyl Iso...
Post a Comment
Read more